期刊文献+

不同分子亚型乳腺癌患者放疗效果分析

原文传递
导出
摘要 目的探讨不同分子亚型对乳腺癌患者放疗效果的影响。方法选取2013年1月至2016年1月徐州市贾汪区人民医院收治的97例乳腺癌患者作为研究对象,根据乳腺癌不同分子亚型分为Luminal A组(19例)、Luminal B组(60例)、Her2阳性组(7例)和三阴性组(11例)。四组患者均接受保乳术联合术后放疗。评价四组治疗后复发和转移情况、平均生存时间和5年内生存率。结果治疗后,四组患者复发率和转移率比较,差异均无统计学意义(P>0.05)。四组平均生存时间和5年生存率比较,差异均有统计学意义(P<0.05)。Luminal A组平均生存时间长于其他三组,Her2阳性组平均生存时间短于其他三组,差异均有统计学意义(P<0.05)。Luminal B组和三阴性组平均生存时间比较,差异无统计学意义(P>0.05)。Luminal A组5年生存率高于Her2阳性组、Luminal B组和三阴性组,差异有统计学意义(P<0.05)。结论不同分子亚型乳腺癌患者术后放疗后生存时间不同,其中Luminal A型乳腺癌患者预后相对较好,而Her-2阳性患者预后最差。
出处 《慢性病学杂志》 2021年第10期1578-1580,共3页 Chronic Pathematology Journal
作者简介 江红,大学本科,副主任医师,研究方向:乳腺及妇科肿瘤;通讯作者:江红,E-mail:y16u2m@163.com
  • 相关文献

参考文献5

二级参考文献43

  • 1Viale G,Regan MM,Maiorano E,et al.Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer:BIG 1-98[J].J Clin Oncol,2007,25(25):3846-3852.
  • 2Rhodes A,Jasani B,Balaton AJ,et al.Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas:Correlation with patient age,assay sensitivity,threshold value,and mammographic screening[J].J Clin Pathol,2000,53(9):688-696.
  • 3Zhang Z,Wang J,Skinner KA,et al.Pathological features and clinical outcomes of breast cancer according to levels of oestrogen receptor expression[J].Histopathology,2014,65(4):508-516.
  • 4Harvey JM,Clark GM,Osbome CK,et al.Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer[J].J Clin Oncol,1999,17(5):1474-1481.
  • 5Elledge RM,Green S,Pugh R,et al.Estrogen receptor(ER)and progesterone receptor(PgR),by ligand-binding assay compared with ER,PgR and pS2,by immunohistocheniistiy in predicting response to tamoxifen in metastatic breast cancer:A Southwest Oncology Group study[J].Int J Cancer,2000,89?2):111-117.
  • 6Hammond ME,Hayes DF,Dowsett M,et al.American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer[J].J Clin Oncol,2010,28(16):2784-2795.
  • 7Wolff AC,Hammond ME,Schwartz JN,et al.American Society of Clinical Oncology/ College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer[J].J Clin Oncol,2007,25(1):118-145.
  • 8Goldhirsch A,Winer EP,Coates AS,et al.Personalizing the treatment of women with early breast cancer:highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2013[J].Ann Oncol,2013,24(9);2206-2223.
  • 9Taylor CR,Levenson RM.Quantification of immunohistochemistry:Issues concerning methods,utility and semiquantitative assessment II[J].Histopathology,2006,49(4):411-424.
  • 10Yaziji H,Taylor CR,Goldstein NS,et al.Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry[J].Appl Immunohistochem Mol Morphol,2008,16(6):513-520.

共引文献243

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部